PE20030702A1 - Inhibidores de pde9 para tratamiento de transtornos cardiovasculares - Google Patents
Inhibidores de pde9 para tratamiento de transtornos cardiovascularesInfo
- Publication number
- PE20030702A1 PE20030702A1 PE2002001070A PE2002001070A PE20030702A1 PE 20030702 A1 PE20030702 A1 PE 20030702A1 PE 2002001070 A PE2002001070 A PE 2002001070A PE 2002001070 A PE2002001070 A PE 2002001070A PE 20030702 A1 PE20030702 A1 PE 20030702A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- ona
- pyrimidin
- dihydro
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
SE REFIERE A COMPUESTOS DE FORMULA I DONDE R1 ES H, ALQUILO C1-C6 DONDE R1 SE UNE A N1 O N2; R2 ES ALQUILO C1-C6, CICLOALQUILO C3-C7, HETEROCICLO DE 5-6 MIEMBROS CON ALQUILO, OH, ALCOXI; R3 ES ALQUILO C1-C6 CON Ar2, CICLOALQUILO C3-C7, ENTRE OTROS; Ar2 ES EL GRUPO a CONDE R4, R5, R6 SON H, HALO, FENOXI, FENILO, CF3, CF3, ENTRE OTROS. CUANDO R1 ESTA UNIDO A N1, R1 ES ALQUILO C1-C6 Y R2 ES PROPILO ENTONCE R3 NO ES METILO SUSTITUIDO CON Ar1; R1 ESTA UNIDO A N1, R1 ES ALQUILO C1-C6, R2 ES METILO ENTONCES R3 NO ES ALQUILO C1-C4 SUSTITUIDO CON Ar1. SON COMPUESTOS PREFERIDOS 5-(-3-CLOROBENZIL)-3-ISOPROPIL-1,6-DIHIDRO-PIRAZOL[4,3-d]PIRIMIDIN-7-ONA, 3-ISOPROPIL-5-(2-FENOXIBENZIL)-1,6-DIHIDRO-PIRAZOL[4,3-d]PIRIMIDIN-7-ONA. 3-(3-PIRIDINIL)-5-(-2-BENCILOXIBENZIL)-1,6-DIHIDRO-PIRAZOL[4,3-d]PIRIMIDIN-7-ONA. 3-ISOPROPIL-5-(2-TRIFLUOROMETOXIBENCIL)-1,6-DIHIDRO-PIRAZOL[4,3-d]PIRIMIDIN-7-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LA FOSFODIESTERASA 9 (PDE9) Y SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0126395A GB0126395D0 (en) | 2001-11-02 | 2001-11-02 | Pyrazolo[4,3]pyrimidine derivatives and their use in treating disease |
GB0130695A GB0130695D0 (en) | 2001-12-21 | 2001-12-21 | Pyrazola[4,3]pyrimidine |
GB0216761A GB0216761D0 (en) | 2002-07-18 | 2002-07-18 | PDE9 Inhibitors for treating cardiovascular disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030702A1 true PE20030702A1 (es) | 2003-08-21 |
Family
ID=27256310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002001070A PE20030702A1 (es) | 2001-11-02 | 2002-10-30 | Inhibidores de pde9 para tratamiento de transtornos cardiovasculares |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1440073A1 (es) |
JP (1) | JP2005511575A (es) |
AR (1) | AR037329A1 (es) |
BR (1) | BR0214096A (es) |
CA (1) | CA2466824A1 (es) |
DO (1) | DOP2002000482A (es) |
HN (1) | HN2002000317A (es) |
MX (1) | MXPA04004171A (es) |
PA (1) | PA8557401A1 (es) |
PE (1) | PE20030702A1 (es) |
SV (1) | SV2004001373A (es) |
TW (1) | TW200300081A (es) |
UY (1) | UY27522A1 (es) |
WO (1) | WO2003037899A1 (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005511500A (ja) | 2001-08-31 | 2005-04-28 | ザ ロックフェラー ユニバーシティー | 脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ1b媒介シグナル伝達の調節 |
AU2002351183B2 (en) * | 2001-12-06 | 2008-05-08 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
DE10238723A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
DE102004004142A1 (de) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine |
DE10320785A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
JP2006525966A (ja) * | 2003-05-09 | 2006-11-16 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 6−シクリルメチル−および6−アルキルメチル置換ピラゾロピリミジン類 |
US8044060B2 (en) | 2003-05-09 | 2011-10-25 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory |
DE10328479A1 (de) | 2003-06-25 | 2005-01-13 | Bayer Ag | 6-Arylamino-5-cyano-4-pyrimidinone |
PL1651612T3 (pl) | 2003-07-22 | 2012-09-28 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
DE102004001873A1 (de) | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
US7067659B2 (en) * | 2004-04-23 | 2006-06-27 | Duke University | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
DE102005024494A1 (de) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Cyanopyrimidinen |
JP5140418B2 (ja) | 2005-06-14 | 2013-02-06 | あすか製薬株式会社 | チエノピリミジン誘導体 |
US20080194592A1 (en) * | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
AU2007256633B2 (en) | 2006-06-06 | 2013-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
AU2007282678B2 (en) | 2006-08-08 | 2012-09-27 | Aska Pharmaceutical Co., Ltd. | Quinazoline derivative |
CA2672591A1 (en) * | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | Treating agent of uropathy |
ES2566774T3 (es) | 2006-12-13 | 2016-04-15 | Aska Pharmaceutical Co., Ltd. | Derivado de quinoxalina |
CA2678575C (en) * | 2007-02-16 | 2013-10-08 | Emisphere Technologies, Inc. | Compounds having a cyclic moiety and compositions for delivering active agents |
NZ580904A (en) * | 2007-05-11 | 2012-02-24 | Pfizer | Amino-heterocyclic compounds for inhibiting pde9 |
WO2009068617A1 (en) | 2007-11-30 | 2009-06-04 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders |
WO2009073210A1 (en) | 2007-12-06 | 2009-06-11 | Intra-Cellular Therapies, Inc | Organic compounds |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
WO2010026214A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
PE20110834A1 (es) | 2008-12-06 | 2011-12-14 | Intra Cellular Therapies Inc | DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1) |
EA201170773A1 (ru) | 2008-12-06 | 2012-01-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
JP5813511B2 (ja) | 2008-12-06 | 2015-11-17 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
BRPI1009287A2 (pt) | 2009-03-05 | 2019-09-24 | Astellas Pharma Inc | composto de quinoxalina |
JP5542196B2 (ja) | 2009-03-31 | 2014-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1−複素環−1,5−ジヒドロ−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体及びpde9aモジュレーターとしてのそれらの使用 |
SG10201507362TA (en) | 2009-08-05 | 2015-10-29 | Intra Cellular Therapies Inc | Novel Regulatory Proteins And Inhibitors |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
JP5894148B2 (ja) | 2010-05-31 | 2016-03-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
WO2012004900A1 (en) * | 2010-07-09 | 2012-01-12 | Aska Pharmaceutical Co., Ltd. | Thienopyrimidine compounds |
PE20130602A1 (es) | 2010-08-12 | 2013-05-25 | Boehringer Ingelheim Int | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a |
RS54834B1 (sr) | 2010-09-07 | 2016-10-31 | Astellas Pharma Inc | Jedinjenja pirazolokvinolina |
CA2810659A1 (en) | 2010-09-07 | 2012-03-15 | Astellas Pharma Inc. | Quinoxaline compound |
EP2649053B1 (en) * | 2010-12-06 | 2015-11-04 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2 |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
EA025380B1 (ru) | 2011-02-25 | 2016-12-30 | Мерк Шарп Энд Домэ Корп. | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов |
MA37958B1 (fr) * | 2011-10-10 | 2018-10-31 | H Lundbeck As | Pde9i ayant un squelette imidazo pyrazinone |
EP3178820B1 (en) | 2012-01-26 | 2017-12-20 | H. Lundbeck A/S | Pde9- inhibitors with imidazo triazinone backbone |
KR20150036245A (ko) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 트리시클릭 화합물 |
CN102786525B (zh) | 2012-08-08 | 2014-12-17 | 中山大学 | N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用 |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP3865484B1 (en) | 2015-07-07 | 2023-11-08 | H. Lundbeck A/S | Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
KR102627790B1 (ko) | 2017-06-01 | 2024-01-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체와 메만틴을 병용한 치매 치료제 |
BR112019023552A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina |
CA3060030A1 (en) | 2017-06-01 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
US11484502B2 (en) | 2017-06-01 | 2022-11-01 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising PDE9 inhibitor |
KR20210053948A (ko) * | 2018-08-31 | 2021-05-12 | 이마라 인크. | 겸상 세포 질환의 치료를 위한 pde9 억제제 |
WO2020182076A1 (zh) * | 2019-03-08 | 2020-09-17 | 南京药捷安康生物科技有限公司 | 磷酸二酯酶抑制剂的用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3939161A (en) * | 1973-10-29 | 1976-02-17 | Abbott Laboratories | 1,3-Dimethyl- 1H-pyrazolo(4,3-D) pyrimidine-7 (6H)-ones |
US4666908A (en) * | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
GB9722520D0 (en) * | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
DE19838705A1 (de) * | 1998-08-26 | 2000-03-02 | Bayer Ag | Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one |
IL139456A0 (en) * | 1999-11-08 | 2001-11-25 | Pfizer | Compounds for the treatment of female sexual dysfunction |
JP2004534733A (ja) * | 2001-02-05 | 2004-11-18 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 血中コレステロール低下剤剤としてのアリール置換アルキルカルボン酸 |
-
2002
- 2002-10-01 HN HN2002000317A patent/HN2002000317A/es unknown
- 2002-10-09 DO DO2002000482A patent/DOP2002000482A/es unknown
- 2002-10-22 BR BR0214096-9A patent/BR0214096A/pt not_active IP Right Cessation
- 2002-10-22 WO PCT/IB2002/004385 patent/WO2003037899A1/en not_active Application Discontinuation
- 2002-10-22 EP EP02777623A patent/EP1440073A1/en not_active Withdrawn
- 2002-10-22 JP JP2003540180A patent/JP2005511575A/ja active Pending
- 2002-10-22 CA CA002466824A patent/CA2466824A1/en not_active Abandoned
- 2002-10-22 MX MXPA04004171A patent/MXPA04004171A/es unknown
- 2002-10-29 PA PA20028557401A patent/PA8557401A1/es unknown
- 2002-10-30 PE PE2002001070A patent/PE20030702A1/es not_active Application Discontinuation
- 2002-10-30 UY UY27522A patent/UY27522A1/es not_active Application Discontinuation
- 2002-10-31 AR ARP020104152A patent/AR037329A1/es unknown
- 2002-11-01 SV SV2002001373A patent/SV2004001373A/es not_active Application Discontinuation
- 2002-11-01 TW TW091132424A patent/TW200300081A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
UY27522A1 (es) | 2003-06-30 |
EP1440073A1 (en) | 2004-07-28 |
WO2003037899A1 (en) | 2003-05-08 |
BR0214096A (pt) | 2004-09-28 |
MXPA04004171A (es) | 2004-09-06 |
HN2002000317A (es) | 2003-05-21 |
JP2005511575A (ja) | 2005-04-28 |
PA8557401A1 (es) | 2003-11-12 |
AR037329A1 (es) | 2004-11-03 |
CA2466824A1 (en) | 2003-05-08 |
TW200300081A (en) | 2003-05-16 |
SV2004001373A (es) | 2004-01-07 |
DOP2002000482A (es) | 2003-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030702A1 (es) | Inhibidores de pde9 para tratamiento de transtornos cardiovasculares | |
PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
PE20020506A1 (es) | Derivados de pirazol fusionados como inhibidores de la proteina cinasa | |
AR054524A1 (es) | Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato | |
PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
DOP2001000271A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes antiinflamatorios y analgésicos. | |
WO2003106428A8 (fr) | Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine | |
HRP20090162T1 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
UY26872A1 (es) | Derivados de la 4- fenil piridina | |
PE20020721A1 (es) | Derivados de quinuclidina como agentes antimuscarinicos m3 | |
ECSP034744A (es) | Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos | |
RU2009117642A (ru) | Применение спирооксиндоловых соединений в качестве терапевтических средств | |
SE0104334D0 (sv) | Therapeutic agents | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
WO2002080846A3 (en) | Epothilone derivatives and methods for making and using the same | |
PE20100737A1 (es) | Nuevos compuestos | |
PE20060380A1 (es) | Derivados de pirido-pirimidina en la prevencion y tratamiento de la proliferacion celular | |
PE20030574A1 (es) | N-[benzoil]heteroarilsulfonamida como agentes antineoplasicos | |
IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
AR054508A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla | |
RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
DE60214401D1 (de) | Hetero-bicyclische crf antagonisten | |
PE20050587A1 (es) | Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales | |
AR033427A1 (es) | Uso de compuestos carbamatos en el tratamiento del dolor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |